By now, we are sure that everyone must be aware about the fact that the trend of using diabetes drugs in order to treat obesity and make people lose fat has been at its peak and there is no chance that this hype will die down anytime soon as people are looking for ways to lose weight. We can tell them right now that the best way to lose weight is by eating clean and exercising daily but we do know that not everyone is able to do that. This is the reason why weight loss surgeries are also done and they have been done for a long time now. Talking about the drugs, Elon Musk shared his weight loss story and told everyone that he took Ozempic for losing extra kilos and this started the whole trend. Now, we have a new report which states that FDA has approved a new drug named Zepbound which is Eli Lily’s diabetes drug and it was known formerly as Mounjaro.

As per this report, “The US Food and Drug Administration approved the type 2 diabetes drug tirzepatide for use in chronic weight management Wednesday, making official the use of a medicine already widely prescribed off-label for weight loss”. FDA shared a press release and revealed that “The drug, called Mounjaro for diabetes, will be called Zepbound for weight loss. Made by Eli Lilly, it’s part of a new class of drugs that includes semaglutide, known as Ozempic for diabetes and Wegovy for weight loss, which have skyrocketed in popularity in recent years”. It is noted that “Zepbound was shown in clinical trials to yield more than 20% average weight loss on higher doses over 72 weeks, stronger results than seen with other approved medicines. The FDA cleared it for people with obesity or those characterized as overweight with at least one weight-related health condition, such as high blood pressure or heart disease, the same indication as for Wegovy. Like similar drugs, it’s taken as a shot patients give themselves once a week, and is recommended on top of a reduced calorie diet and increased exercise”.

FDA also mentions that “Obesity and overweight are serious conditions that can be associated with some of the leading causes of death such as heart disease, stroke and diabetes”. “In light of increasing rates of both obesity and overweight in the United States, today’s approval addresses an unmet medical need.”